Efficacy of Low-Dose Tocilizumab on a Relapse of Adult-Onset Still’s Disease
Still’s disease is an inflammatory disorder of unknown etiology. First-line therapy is based on corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) but the frequency of relapses and corticosteroid-induced adverse events are limiting factors. The efficacy of intravenous tocilizumab (TC...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karolinum Press
2016-04-01
|
| Series: | Acta Medica |
| Subjects: |
| _version_ | 1818327762102910976 |
|---|---|
| author | Xavier Vandemergel Frédéric Vandergheynst |
| author_facet | Xavier Vandemergel Frédéric Vandergheynst |
| author_sort | Xavier Vandemergel |
| collection | DOAJ |
| description | Still’s disease is an inflammatory disorder of unknown etiology. First-line therapy is based on corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) but the frequency of relapses and corticosteroid-induced adverse events are limiting factors. The efficacy of intravenous tocilizumab (TCZ) has been shown at a dose of 8 mg/kg but the corticosteroid-sparing effect of intravenous low-dose TCZ followed by subcutaneous (SC) injection in the course of the disease has been poorly investigated. We report the case of a 28-year old Caucasian woman presenting a relapse of Still’s disease eleven months after diagnosis under treatment with 6 mg of methylprednisolone. TCZ at a dose of 4 mg/kg every 2 weeks was combined with 32 mg of methylprednisolone, followed by 162 mg SC every 3 weeks. Evolution was rapidly favourable with a decrease in corticosteroid doses. We reviewed previously published cases. |
| first_indexed | 2024-12-13T12:21:25Z |
| format | Article |
| id | doaj.art-f35f76b660ee4fc782a709d7b0cfd57a |
| institution | Directory Open Access Journal |
| issn | 1211-4286 1805-9694 |
| language | English |
| last_indexed | 2024-12-13T12:21:25Z |
| publishDate | 2016-04-01 |
| publisher | Karolinum Press |
| record_format | Article |
| series | Acta Medica |
| spelling | doaj.art-f35f76b660ee4fc782a709d7b0cfd57a2022-12-21T23:46:35ZengKarolinum PressActa Medica1211-42861805-96942016-04-01591222510.14712/18059694.2016.513665Efficacy of Low-Dose Tocilizumab on a Relapse of Adult-Onset Still’s DiseaseXavier VandemergelFrédéric VandergheynstStill’s disease is an inflammatory disorder of unknown etiology. First-line therapy is based on corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) but the frequency of relapses and corticosteroid-induced adverse events are limiting factors. The efficacy of intravenous tocilizumab (TCZ) has been shown at a dose of 8 mg/kg but the corticosteroid-sparing effect of intravenous low-dose TCZ followed by subcutaneous (SC) injection in the course of the disease has been poorly investigated. We report the case of a 28-year old Caucasian woman presenting a relapse of Still’s disease eleven months after diagnosis under treatment with 6 mg of methylprednisolone. TCZ at a dose of 4 mg/kg every 2 weeks was combined with 32 mg of methylprednisolone, followed by 162 mg SC every 3 weeks. Evolution was rapidly favourable with a decrease in corticosteroid doses. We reviewed previously published cases.Still’s diseaseTocilizumabRelapse |
| spellingShingle | Xavier Vandemergel Frédéric Vandergheynst Efficacy of Low-Dose Tocilizumab on a Relapse of Adult-Onset Still’s Disease Acta Medica Still’s disease Tocilizumab Relapse |
| title | Efficacy of Low-Dose Tocilizumab on a Relapse of Adult-Onset Still’s Disease |
| title_full | Efficacy of Low-Dose Tocilizumab on a Relapse of Adult-Onset Still’s Disease |
| title_fullStr | Efficacy of Low-Dose Tocilizumab on a Relapse of Adult-Onset Still’s Disease |
| title_full_unstemmed | Efficacy of Low-Dose Tocilizumab on a Relapse of Adult-Onset Still’s Disease |
| title_short | Efficacy of Low-Dose Tocilizumab on a Relapse of Adult-Onset Still’s Disease |
| title_sort | efficacy of low dose tocilizumab on a relapse of adult onset still s disease |
| topic | Still’s disease Tocilizumab Relapse |
| work_keys_str_mv | AT xaviervandemergel efficacyoflowdosetocilizumabonarelapseofadultonsetstillsdisease AT fredericvandergheynst efficacyoflowdosetocilizumabonarelapseofadultonsetstillsdisease |